1. At a Glance
There are pharmaceutical companies that grow because pricing turns favourable. There are companies that grow because one lucky molecule catches fire. And then there are businesses that change their earnings architecture so quietly that the market notices only after the compounding has already happened.
Granules India may be trying to move into that third category.
Look at what just happened.
FY26 revenue crossed ₹53,656 million (₹5,366 crore), up 20%. EBITDA rose 25% to ₹11,851 million. PAT climbed 19% to ₹5,950 million. Gross margins touched 65%, the highest in company history. Net debt to EBITDA collapsed from 0.75x to 0.34x.
That is not normal for a company many still lazily classify as a commodity generics manufacturer.
Something else is happening.
The old Granules story was simple. Cheap APIs. Big volumes. Operational efficiency. Paracetamol king.
The emerging Granules story looks different.
Complex generics contribution rising.
Peptide CDMO emerging.
Europe suddenly accelerating.
Genome Valley capacity kicking in.
Balance sheet de-risking.
Warning-letter overhang gradually ring-fenced.
This starts looking less like a plain vanilla generic manufacturer and more like a business trying to move up the pharma value stack.
And markets usually pay very differently for those two categories.
Interesting part?
Despite all this, stock P/E sits around 29x versus many richer pharma peers.
Question:
Is the market seeing Granules as the old Granules while management is building a very different beast?
That is where things become interesting.
Because beneath reported numbers, the business mix has changed materially.
Finished dosages now 74-77% of revenues.
Complex generics 43% of formulations vs 31% earlier.
CDMO has emerged as a fourth revenue engine.
North America still dominant, but Europe suddenly behaving like it drank three espressos.
Meanwhile gross margin expansion has been structural, not accidental.
From 50% in FY22.
To 65% in FY26.
That is not commodity behaviour.
That is mix upgrade.
And markets often misread mix upgrades for several years.
Then comes the other side of the detective story.
Inventory days have balloononed to 326.
Cash conversion cycle at 256 days is not elegant.
Promoter holding slipped to 38.02%.
USFDA warning letter overhang is unresolved.
Peptide business still early.
So this is not a clean fairytale.
Which makes it more interesting.
Because investing is rarely about spotless companies.
It is often about whether improving reality is ahead of improving perception.
Granules may be sitting exactly there.
And if management has indeed walked the talk from old concalls—as the FY26 outcomes suggest—they may have earned the right to be examined less as a cheap generic player and more as a transition story.
That is a very different valuation conversation.
But before jumping there, ask yourself:
Are we looking at a pharmaceutical company.
Or a business quietly re-rating into a specialty platform while everyone still calls it paracetamol?
That question may decide the next five years.
2. Introduction
Granules has always been slightly misunderstood.
Too large to be niche.
Too specialized to be commodity.
Too boring to excite momentum crowds.
Too profitable to ignore.
Classic market blind spot.
For years, the company’s reputation got trapped in legacy molecules.
Paracetamol.
Metformin.
Ibuprofen.
Volume-driven APIs.
Useful.
Profitable.
But rarely glamorous.
Markets love glamour.
Markets underprice disciplined boredom.
Granules has exploited that for decades.
But FY26 suggests something deeper.
This may be less about being a low-cost manufacturer and more about portfolio migration.
Management has been speaking for several years about moving toward:
- Complex generics
- Controlled substances
- Oncology
- Peptides
- CDMO
- Multi-site manufacturing risk mitigation
Usually management presentations say beautiful things.
Reality says ruder things.
Here reality seems cooperating.
Jan 2026 concall promised:
- peptide breakeven in Q4
- mix-driven margin expansion
- GLS commercialization
- complex generics ramp
Q4 delivered all four.
Management appears to have walked the talk.
That matters.
Because execution credibility compounds faster than earnings.
There is also something unusual in capital allocation.
₹5,547 million capex in FY26.
Yet leverage dropped.
Normally Indian investors see capex and brace for balance-sheet indigestion.
Here capex came with deleveraging.
That deserves attention.
Then there is the acquisition of Senn Chemicals.
Many thought distraction.
Could become optionality.
Big difference.
And then one spicy ingredient:
Preferential issue.
₹1,762 crore total fundraising.
Now ask:
Why raise growth capital when leverage already falling?
Defensive?
Offensive?
Both?
Detective hats on.
Because sometimes capital raises signal stress.
Sometimes they fund the next compounding leg.
Which one is this?
That may be one of the central puzzles.
3. Business Model – What Exactly Do They Do?
Imagine a pharmaceutical factory that refuses to remain one factory.
That is Granules.
It manufactures ingredients.
Then intermediates.
Then finished doses.
Then increasingly complex formulations.
Then now peptide CDMO.
Basically it started selling flour.
Then opened a bakery.
Now wants to sell premium desserts.
That is forward integration.
And margins usually like that.
Three historical engines:
API
Old warhorse.
Still meaningful.
Still cash-generative.
Still not glamorous.
PFI
Middle layer most people ignore.
But often where process edge hides.
Finished Dosages
Where value moved.
And where management wants
